sharetrader
Page 8 of 8 FirstFirst ... 45678
Results 71 to 72 of 72
  1. #71
    percy
    Join Date
    Oct 2009
    Location
    christchurch
    Posts
    17,222

    Default

    Bell Potter 2023 picks:
    Aroa Biosurgery (ARX)
    Aroa Biosurgery is a commercial stage
    medical device company that operates
    within the complex wound care and
    soft tissue reconstruction sector.
    The portfolio includes Endoform/
    Myriad/Symphony (complex wounds)
    and the OviTex devices (breast &
    hernia surgery) which are distributed
    through TELA Bio in the US. 1H23
    Revenue NZ$29.3m (48% revenue
    growth on 2H22) has been driven by
    Myriad and OviTex sales. Aroa has
    maintained its FY23 revenue guidance
    of NZ$62-64m, gross product margin
    of 84% and normalised EBITDA to be
    approximately breakeven. Key catalysts
    include the ongoing commercialisation
    of Myriad, Symphony launch during
    CY23 and product line extension
    involving OviTex.
    Buy, Price Target au$1.40

  2. #72
    Member
    Join Date
    May 2020
    Location
    Wellington
    Posts
    116

    Default

    ASX ANNOUNCEMENT/MEDIA RELEASE31 JULY 2023A R OA B IO S UR GE RY J UN E 20 2 3 4 C – C OM M EN T A RY
    Financial Highlights
    • Increased cash receipts from customers of NZ$15.2 million during the quarter, compared toreceipts of NZ$12.3 million for the prior quarter.
    • In line with expectations, net cash outflow from operations of NZ$4.8 million for the quarter,compared to the prior quarter outflow of NZ$1.9 million. This primarily reflected typical postfinancial year payments and a planned operating loss for the quarter. Net cash outflow frominvesting activities was NZ$1.3 million for the quarter, reflecting further investment intoadditional manufacturing plant & equipment capacity.
    • Strong cash balance of NZ$38.5 million as at 30 June 2023.
    • FY24 product revenue guidance maintained at NZ$72-75 million1(25-30% increase on FY23on a constant currency basis2).
    • FY24 product gross margin guidance maintained at 85%.
    • FY24 normalised3 EBITDA profit guidance maintained at NZ$1-2 million.

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •